Flexibility and small pockets at protein-protein interfaces: New insights into druggability

Progress in Biophysics and Molecular Biology

Volumn 119, Issue 1, 2015, Pages 2-9

  Jubb, Harry ^a   Blundell, Tom L ^a   Ascher, David B ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

Hotspots; Inhibitors druggability; Protein protein interfaces

Indexed keywords

PROTEIN;

CHEMISTRY; DRUG DEVELOPMENT; HUMAN; METABOLISM; PROCEDURES; PROTEIN ANALYSIS;

DRUG DISCOVERY; HUMANS; PROTEIN INTERACTION MAPPING; PROTEINS;

EID: 84940893103     PISSN: 00796107     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbiomolbio.2015.01.009     Document Type: Review

References (104)

1. Arkin M.R., Tang Y., Wells J.A. Small-molecule inhibitors of protein-protein interactions: progressing toward the reality. Chem. Biol. 2014, 21:1102-1114.
2. Basse M.J., Betzi S., Bourgeas R., Bouzidi S., Chetrit B., Hamon V., Morelli X., Roche P. 2P2Idb: a structural database dedicated to orthosteric modulation of protein-protein interactions. Nucleic Acids Res. 2013, 41:D824-D827.
3. Ben-Shimon A., Eisenstein M. Computational mapping of anchoring spots on protein surfaces. J. Mol. Biol. 2010, 402:259-277.
4. Bento A.P., Gaulton A., Hersey A., Bellis L.J., Chambers J., Davies M., Kruger F.A., Light Y., Mak L., McGlinchey S., Nowotka M., Papadatos G., Santos R., Overington J.P. The ChEMBL bioactivity database: an update. Nucleic Acids Res. 2014, 42:D1083-D1090.
5. Bernal F., Wade M., Godes M., Davis T.N., Whitehead D.G., Kung A.L., Wahl G.M., Walensky L.D. A stapled p53 helix overcomes HDMX-mediated suppression of p53. Cancer Cell. 2010, 18:411-422.
6. Bickerton G.R., Higueruelo A.P., Blundell T.L. Comprehensive, atomic-level characterization of structurally characterized protein-protein interactions: the PICCOLO database. BMC Bioinforma. 2011, 12:313.
7. Birchmeier C., Birchmeier W., Gerhardi E., Woude G.F.V. Met, metastasis, motility and more. Nat. Rev. Mol. Cell. Biol. 2003, 4:915-925.
8. Blaszczyk M., Chirgadze D.Y., Youles M.Y., de Jonge H., Kemp L., Sobkowicz A., Petoukhov M.V., Zhou M., Nessen M.A., Di Cara D., Winter A., Iamele L., Strezlecki L., Niemann H.H., Mulloy B., Robinson C.V., Svergun D.I., Blundell T.L., Gherardi E.G. Solution and Crystal Structures Define the Binding Site of the NK1 Fragment of Hepatocyte Growth Factor/Scatter Factor on the SEMA Domain of the MET Receptor 2015, (in preparation).
9. Blundell T. Conformation and molecular-biology of polypeptide hormones .2. Glucagon. Trends Biochem. Sci. 1979, 4:80-83.
10. Blundell T., Wood S. The conformation, flexibility, and dynamics of polypeptide hormones. Annu. Rev. Biochem. 1982, 51:123-154.
11. Blundell T.L., Burke D.F., Chirgadze D., Dhanaraj V., Hyvonen M., Innis C.A., Parisini E., Pellegrini L., Sayed M., Sibanda B.L. Protein-protein interactions in receptor activation and intracellular signalling. Biol. Chem. 2000, 381:955-959.
12. Blundell T.L., Jhoti H., Abell C. High-throughput crystallography for lead discovery in drug design. Nat. Rev. Drug Discov. 2002, 1:45-54.
13. Blundell T.L., Sibanda B.L., Montalvao R.W., Brewerton S., Chelliah V., Worth C.L., Harmer N.J., Davies O., Burke D. Structural biology and bioinformatics in drug design: opportunities and challenges for target identification and lead discovery. Philos. Trans. R. Soc. Lond. B Biol. Sci. 2006, 361:413-423.
14. Bogan A.A., Thorn K.S. Anatomy of hot spots in protein interfaces. J. Mol. Biol. 1998, 280:1-9.
15. Bolanos-Garcia V.M., Wu Q., Ochi T., Chirgadze D.Y., Sibanda B.L., Blundell T.L. Spatial and temporal organization of multi-protein assemblies: achieving sensitive control in information-rich cell-regulatory systems. Philos. Trans. R. Soc. a-Math. Phys. Eng. Sci. 2012, 370:3023-3039.
16. Bonvin A.M.J.J., Vis H., Breg J.N., Burgering M.J.M., Boelens R., Kaptein R. Nuclear-magnetic-resonance solution structure of the arc repressor using relaxation matrix calculations. J. Mol. Biol. 1994, 236:328-341.
17. Bourgeas R., Basse M.J., Morelli X., Roche P. Atomic analysis of protein-protein interfaces with known inhibitors: the 2P2I database. PLoS One 2010, 5.
18. Braun W., Wider G., Lee K.H., Wuthrich K. Conformation of glucagon in a lipid water interphase by H-1 nuclear magnetic-resonance. J. Mol. Biol. 1983, 169:921-948.
19. Brunner H.R., Gavras H., Laragh J.H. Angiotensin-II blockade in man by sar1-ala8-angiotensin II for understanding and treatment of high blood-pressure. Lancet 1973, 2:1045-1048.
20. Cao B., Su Y., Oskarsson M., Zhao P., Kort E.J., Fisher R.J., Wang L.M., Vande Woude G.F. Neutralizing monoclonal antibodies to hepatocyte growth factor/scatter factor (HGF/SF) display antitumor activity in animal models. Proc. Natl. Acad. Sci. U. S. A. 2001, 98:7443-7448.
21. Chang Y.S., Graves B., Guerlavais V., Tovar C., Packman K., To K.H., Olson K.A., Kesavan K., Gangurde P., Mukherjee A., Baker T., Darlak K., Elkin C., Filipovic Z., Qureshi F.Z., Cai H., Berry P., Feyfant E., Shi X.E., Horstick J., Annis D.A., Manning A.M., Fotouhi N., Nash H., Vassilev L.T., Sawyer T.K. Stapled alpha-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E3445-E3454.
22. Chen Y.C., Chen H.C., Yang J.M. DAPID: a 3D-domain annotated protein-protein interaction database. Genome Inf. 2006, 17:206-215.
23. Chirgadze D.Y., Hepple J.P., Zhou H., Byrd R.A., Blundell T.L., Gherardi E. Crystal structure of the NK1 fragment of HGF/SF suggests a novel mode for growth factor dimerization and receptor binding. Nat. Struct. Biol. 1999, 6:72-79.
24. Clackson T., Wells J.A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267:383-386.
25. Cukuroglu E., Engin H.B., Gursoy A., Keskin O. Hot spots in protein-protein interfaces: towards drug discovery. Prog. Biophys. Mol. Biol. 2014, 116:165-173.
26. De Genst E., Silence K., Decanniere K., Conrath K., Loris R., Kinne J., Muyldermans S., Wyns L. Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:4586-4591.
27. Desmyter A., Transue T.R., Ghahroudi M.A., Thi M.H., Poortmans F., Hamers R., Muyldermans S., Wyns L. Crystal structure of a camel single-domain VH antibody fragment in complex with lysozyme. Nat. Struct. Biol. 1996, 3:803-811.
28. Fletcher S., Hamilton A.D. Protein surface recognition and proteomimetics: mimics of protein surface structure and function. Curr. Opin. Chem. Biol. 2005, 9:632-638.
29. Fuller J.C., Burgoyne N.J., Jackson R.M. Predicting druggable binding sites at the protein-protein interface. Drug Discov. Today 2009, 14:155-161.
30. Gaulton A., Bellis L.J., Bento A.P., Chambers J., Davies M., Hersey A., Light Y., McGlinchey S., Michalovich D., Al-Lazikani B., Overington J.P. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res. 2012, 40:D1100-D1107.
31. Guo W., Wisniewski J.A., Ji H. Hot spot-based design of small-molecule inhibitors for protein-protein interactions. Bioorg. Med. Chem. Lett. 2014.
32. Hajduk P.J., Greer J. A decade of fragment-based drug design: strategic advances and lessons learned. Nat. Rev. Drug Discov. 2007, 6:211-219.
33. Hamers-Casterman C., Atarhouch T., Muyldermans S., Robinson G., Hamers C., Songa E.B., Bendahman N., Hamers R. Naturally occurring antibodies devoid of light chains. Nature 1993, 363:446-448.
34. Hamon V., Bourgeas R., Ducrot P., Theret I., Xuereb L., Basse M.J., Brunel J.M., Combes S., Morelli X., Roche P. 2P2I HUNTER: a tool for filtering orthosteric protein-protein interaction modulators via a dedicated support vector machine. J. R. Soc. Interface 2014, 11:20130860.
35. Hartmann G., Prospero T., Brinkmann V., Ozcelik O., Winter G., Hepple J., Batley S., Bladt F., Sachs M., Birchmeier C., Birchmeier W., Gherardi E. Engineered mutants of HGF/SF with reduced binding to heparan sulphate proteoglycans, decreased clearance and enhanced activity in vivo. Curr. Biol. 1998, 8:125-134.
36. Hendlich M., Rippmann F., Barnickel G. LIGSITE: automatic and efficient detection of potential small molecule-binding sites in proteins. J. Mol. Graph Model 1997, 15:359-363. 389.
37. Higueruelo A.P., Jubb H., Blundell A. Multiprotein assemblies: modulating cell activity through targeting protein-protein interfaces. Biomolecular Forms and Functions: a Celebration of 50 Years of the Ramachandran Map 2013, 1-13. IISc Press and World Scientific. M. Ed Nansal, N. Srinivasan (Eds.).
38. Higueruelo A.P., Jubb H., Blundell T.L. TIMBAL v2: update of a database holding small molecules modulating protein-protein interactions. Database J. Biol. Databases Curation 2013.
39. Higueruelo A.P., Schreyer A., Bickerton G.R., Blundell T.L., Pitt W.R. What can we learn from the evolution of protein-ligand interactions to aid the design of new therapeutics?. PLoS One 2012, 7:e51742.
40. Higueruelo A.P., Schreyer A., Bickerton G.R.J., Pitt W.R., Groom C.R., Blundell T.L. Atomic interactions and profile of small molecules disrupting protein-protein interfaces: the TIMBAL database. Chem. Biol. Drug Des. 2009, 74:457-467.
41. Holliger P., Hudson P.J. Engineered antibody fragments and the rise of single domains. Nat. Biotechnol. 2005, 23:1126-1136.
42. Holmes O., Pillozzi S., Deakin J.A., Carafoli F., Kemp L., Butler P.J.G., Lyon M., Gherardi E. Insights into the structure/function of hepatocyte growth factor/scatter factor from studies with individual domains. J. Mol. Biol. 2007, 367:395-408.
43. Hopkins A.L., Groom C.R. The druggable genome. Nat. Rev. Drug Discov. 2002, 1:727-730.
44. Huggins D.J., Marsh M., Payne M.C. Thermodynamic properties of water molecules at a protein-protein interaction surface. J. Chem. Theory Comput. 2011, 7:3514-3522.
45. Jones S., Thornton J.M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:13-20.
46. Jubb H., Higueruelo A.P., Winter A., Blundell T.L. Structural biology and drug discovery for protein-protein interactions. Trends Pharmacol. Sci. 2012, 33:241-248.
47. Jubb, H., Pitt, W.R., Shi, J., Baker, T., Lawson, A.D.G., Blundell, T.L., 2015 (in preparation).
48. Kalidas Y., Chandra N. PocketDepth: a new depth based algorithm for identification of ligand binding sites in proteins. J. Struct. Biol. 2008, 161:31-42.
49. Kastritis P.L., Bonvin A.M. On the binding affinity of macromolecular interactions: daring to ask why proteins interact. J. R. Soc. Interface 2013, 10:20120835.
50. Kawabata T. Detection of multiscale pockets on protein surfaces using mathematical morphology. Proteins 2010, 78:1195-1211.
51. Kirchhofer D., Yao X.Y., Peek M., Eigenbrot C., Lipari M.T., Billeci K.L., Maun H.R., Moran P., Santell L., Wiesmann C., Lazarus R.A. Structural and functional basis of the serine protease-like hepatocyte growth factor b-chain in met binding and signaling. J. Biol. Chem. 2004, 279:39915-39924.
52. Kishan K.V.R., Scita G., Wong W.T., DiFiore P.P., Newcomer M.E. The SH3 domain of Eps8 exists as a novel intertwined dimer. Nat. Struct. Biol. 1997, 4:739-743.
53. Koes D., Khoury K., Huang Y., Wang W., Bista M., Popowicz G.M., Wolf S., Holak T.A., Domling A., Camacho C.J. Enabling large-scale design, synthesis and validation of small molecule protein-protein antagonists. PLoS One 2012, 7:e32839.
54. Koes D.R., Camacho C.J. PocketQuery: protein-protein interaction inhibitor starting points from protein-protein interaction structure. Nucleic Acids Res. 2012, 40:W387-W392.
55. Koes D.R., Camacho C.J. Small-molecule inhibitor starting points learned from protein-protein interaction inhibitor structure. Bioinformatics 2012, 28:784-791.
56. Kozakov D., Hall D.R., Chuang G.Y., Cencic R., Brenke R., Grove L.E., Beglov D., Pelletier J., Whitty A., Vajda S. Structural conservation of druggable hot spots in protein-protein interfaces. Proc. Natl. Acad. Sci. U. S. A. 2011, 108:13528-13533.
57. Kuenemann M.A., Bourbon L.M., Labbe C.M., Villoutreix B.O., Sperandio O. Which three-dimensional characteristics make efficient inhibitors of protein-protein interactions?. J. Chem. Inf. Model 2014, 54:3067-3079.
58. Laurie A.T., Jackson R.M. Q-SiteFinder: an energy-based method for the prediction of protein-ligand binding sites. Bioinformatics 2005, 21:1908-1916.
59. Lauwereys M., Arbabi Ghahroudi M., Desmyter A., Kinne J., Holzer W., De Genst E., Wyns L., Muyldermans S. Potent enzyme inhibitors derived from dromedary heavy-chain antibodies. EMBO J. 1998, 17:3512-3520.
60. Lawson A.D.G. Antibody-enabled small-molecule drug discovery. Nat. Rev. Drug Discov. 2012, 11:519-525.
61. Li W., Bengtson M.H., Ulbrich A., Matsuda A., Reddy V.A., Orth A., Chanda S.K., Batalov S., Joazeiro C.A. Genome-wide and functional annotation of human E3 ubiquitin ligases identifies MULAN, a mitochondrial E3 that regulates the organelle's dynamics and signaling. PLoS One 2008, 3:e1487.
62. Li W., Keeble A.H., Giffard C., James R., Moore G.R., Kleanthous C. Highly discriminating protein-protein interaction specificities in the context of a conserved binding energy hotspot. J. Mol. Biol. 2004, 337:743-759.
63. Li X., Keskin O., Ma B., Nussinov R., Liang J. Protein-protein interactions: hot spots and structurally conserved residues often locate in complemented pockets that pre-organized in the unbound states: implications for docking. J. Mol. Biol. 2004, 344:781-795.
64. Lokker N.A., Mark M.R., Luis E.A., Bennett G.L., Robbins K.A., Baker J.B., Godowski P.J. Structure-function analysis of hepatocyte growth factor - identification of variants that lack mitogenic activity yet retain high affinity receptor binding. EMBO J. 1992, 11:2503-2510.
65. London N., Raveh B., Movshovitz-Attias D., Schueler-Furman O. Can self-inhibitory peptides be derived from the interfaces of globular protein-protein interactions?. Proteins 2010, 78:3140-3149.
66. London N., Raveh B., Schueler-Furman O. Druggable protein-protein interactions-from hot spots to hot segments. Curr. Opin. Chem. Biol. 2013, 17:952-959.
67. Loving K.A., Lin A., Cheng A.C. Structure-based druggability assessment of the mammalian structural proteome with inclusion of light protein flexibility. PLoS Comput Biol. 2014, 10:e1003741.
68. Moellering R.E., Cornejo M., Davis T.N., Del Bianco C., Aster J.C., Blacklow S.C., Kung A.L., Gilliland D.G., Verdine G.L., Bradner J.E. Direct inhibition of the NOTCH transcription factor complex. Nature 2009, 462:182-188.
69. Morita M., Nakamura S., Shimizu K. Highly accurate method for ligand-binding site prediction in unbound state (apo) protein structures. Proteins 2008, 73:468-479.
70. Murray C.W., Blundell T.L. Structural biology in fragment-based drug design. Curr. Opin. Struct. Biol. 2010, 20:497-507.
71. Muyldermans S., Atarhouch T., Saldanha J., Barbosa J.A., Hamers R. Sequence and structure of VH domain from naturally occurring camel heavy chain immunoglobulins lacking light chains. Protein Eng. 1994, 7:1129-1135.
72. Neugebauer A., Hartmann R.W., Klein C.D. Prediction of protein-protein interaction inhibitors by chemoinformatics and machine learning methods. J. Med. Chem. 2007, 50:4665-4668.
73. Oltersdorf T., Elmore S.W., Shoemaker A.R., Armstrong R.C., Augeri D.J., Belli B.A., Bruncko M., Deckwerth T.L., Dinges J., Hajduk P.J., Joseph M.K., Kitada S., Korsmeyer S.J., Kunzer A.R., Letai A., Li C., Mitten M.J., Nettesheim D.G., Ng S., Nimmer P.M., O'Connor J.M., Oleksijew A., Petros A.M., Reed J.C., Shen W., Tahir S.K., Thompson C.B., Tomaselli K.J., Wang B., Wendt M.D., Zhang H., Fesik S.W., Rosenberg S.H. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature 2005, 435:677-681.
74. Pagliaro L., Felding J., Audouze K., Nielsen S.J., Terry R.B., Krog-Jensen C., Butcher S. Emerging classes of protein-protein interaction inhibitors and new tools for their development. Curr. Opin. Chem. Biol. 2004, 8:442-449.
75. Pal A., Chakrabarti P., Bahadur R., Rodier F., Janin J. Peptide segments in protein-protein interfaces. J. Biosci. 2007, 32:101-111.
76. Pawson T., Nash P. Assembly of cell regulatory systems through protein interaction domains. Science 2003, 300:445-452.
77. Pellegrini L., Yu D.S., Lo T., Anand S., Lee M., Blundell T.L., Venkitaraman A.R. Insights into DNA recombination from the structure of a RAD51-BRCA2 complex. Nature 2002, 420:287-293.
78. Petrelli A., Circosta P., Granziero L., Mazzone M., Pisacane A., Fenoglio S., Comoglio P.M., Giordano S. Ab-induced ectodomain shedding mediates hepatocyte growth factor receptor down-regulation and hampers biological activity. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5090-5095.
79. Pires D.E., Ascher D.B., Blundell T.L. mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics 2014, 30:335-342.
80. Raj M., Bullock B.N., Arora P.S. Plucking the high hanging fruit: a systematic approach for targeting protein-protein interactions. Bioorg. Med. Chem. 2013, 21:4051-4057.
81. Rajamani D., Thiel S., Vajda S., Camacho C.J. Anchor residues in protein-protein interactions. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11287-11292.
82. Reynes C., Host H., Camproux A.C., Laconde G., Leroux F., Mazars A., Deprez B., Fahraeus R., Villoutreix B.O., Sperandio O. Designing focused chemical libraries enriched in protein-protein interaction inhibitors using machine-learning methods. PLoS Comput Biol. 2010, 6:e1000695.
83. Sasaki K., Dockerill S., Adamiak D.A., Tickle I.J., Blundell T. X-ray analysis of glucagon and its relationship to receptor binding. Nature 1975, 257:751-757.
84. Schwyzer R., Kriwaczek V.M., Baumann K., Haller H.R., Wider G., Wiltzius P. Hormone-receptor interactions - study of the binding of hormone-substituted tobacco mosaic-virus to membrane-vesicles by dynamic light-scattering and by transient electric birefringence. Pure Appl. Chem. 1979, 51:831-835.
85. Scott D.E., Ehebauer M.T., Pukala T., Marsh M., Blundell T.L., Venkitaraman A.R., Abell C., Hyvonen M. Using a fragment-based approach to target protein-protein interactions. Chembiochem 2013, 14:332-342.
86. Shin D.S., Pellegrini L., Daniels D.S., Yelent B., Craig L., Bates D., Yu D.S., Shivji M.K., Hitomi C., Arvai A.S., Volkmann N., Tsuruta H., Blundell T.L., Venkitaraman A.R., Tainer J.A. Full-length archaeal Rad51 structure and mutants: mechanisms for RAD51 assembly and control by BRCA2. Embo J. 2003, 22:4566-4576.
87. Shuker S.B., Hajduk P.J., Meadows R.P., Fesik S.W. Discovering high-affinity ligands for proteins: SAR by NMR. Science 1996, 274:1531-1534.
88. Spinelli S., Frenken L., Bourgeois D., de Ron L., Bos W., Verrips T., Anguille C., Cambillau C., Tegoni M. The crystal structure of a llama heavy chain variable domain. Nat. Struct. Biol. 1996, 3:752-757.
89. Stamos J., Lazarus R.A., Yao X., Kirchhofer D., Wiesmann C. Crystal structure of the HGF beta-chain in complex with the sema domain of the met receptor. EMBO J. 2004, 23:2325-2335.
90. Stein A., Ceol A., Aloy P. 3did: identification and classification of domain-based interactions of known three-dimensional structure. Nucleic Acids Res. 2011, 39:D718-D723.
91. Stewart M.L., Fire E., Keating A.E., Walensky L.D. The MCL-1 BH3 helix is an exclusive MCL-1 inhibitor and apoptosis sensitizer. Nat. Chem. Biol. 2010, 6:595-601.
92. Stijlemans B., Conrath K., Cortez-Retamozo V., Van Xong H., Wyns L., Senter P., Revets H., De Baetselier P., Muyldermans S., Magez S. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J. Biol. Chem. 2004, 279:1256-1261.
93. Tolbert W.D., Daugherty J., Gao C., Xie Q., Miranti C., Gherardi E., Woude G.V., Xu H.E. A mechanistic basis for converting a receptor tyrosine kinase agonist to an antagonist. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:14592-14597.
94. Tuncbag N., Kar G., Keskin O., Gursoy A., Nussinov R. A survey of available tools and web servers for analysis of protein-protein interactions and interfaces. Brief. Bioinform. 2009, 10:217-232.
95. Ultsch M., Lokker N.A., Godowski P.J., Vos A.M.d Crystal structure of the NK1 fragment of human hepatocyte growth factor at 2.0 Å resolution. Structure 1998, 6:1383-1393.
96. Villoutreix B.O., Kuenemann M.A., Poyet J.L., Bruzzoni-Giovanelli H., Labbe C., Lagorce D., Sperandio O., Miteva M.A. Drug-like protein-protein interaction modulators: challenges and opportunities for drug discovery and chemical biology. Mol. Inf. 2014, 33:414-437.
97. Villoutreix B.O., Lagorce D., Labbe C.M., Sperandio O., Miteva M.A. One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. Drug Discov. Today 2013, 18:1081-1089.
98. Watkins A.M., Arora P.S. Anatomy of beta-strands at protein-protein interfaces. ACS Chem. Biol. 2014, 9:1747-1754.
99. Wells J.A., McClendon C.L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450:1001-1009.
100. Winter A., Higueruelo A.P., Marsh M., Sigurdardottir A., Pitt W.R., Blundell T.L. Biophysical and computational fragment-based approaches to targeting protein-protein interactions: applications in structure-guided drug discovery. Q. Rev. Biophys. 2012, 45:383-426.
101. Wright P.E., Dyson H.J. Intrinsically unstructured proteins: re-assessing the protein structure-function paradigm. J. Mol. Biol. 1999, 293:321-331.
102. Wright P.E., Dyson H.J. Linking folding and binding. Curr. Opin. Struct. Biol. 2009, 19:31-38.
103. Youles M., Holmes O., Petoukhov M.V., Nessen M.A., Stivala S., Svergun D.I., Gherardi E. Engineering the NK1 fragment of hepatocyte growth factor/scatter factor as a MET receptor antagonist. J. Mol. Biol. 2008, 377:616-622.
104. Zerbe B.S., Hall D.R., Vajda S., Whitty A., Kozakov D. Relationship between hot spot residues and ligand binding hot spots in protein-protein interfaces. J. Chem. Inf. Model 2012, 52:2236-2244.